Medical/Pharmaceuticals
CStone presents registrational bridging study data for GAVRETO® (pralsetinib) highlighting efficacy and safety in Chinese patients with advanced RET fusion-positive non-small cell lung cancer at IASLC WCLC 2021
SUZHOU, China, Sept. 9, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology therapies and precision medicines, today announced that efficacy and safety data from a...
2021-09-09 08:00
4748
HaemaLogiX raises $10 million to advance multiple myeloma treatments
* HaemaLogiX completes a fully subscribed $10 million share placement and welcomes Platinum Asset Management as core new institutional investor within its Platinum International Health Care Fund * Funding underpins HaemaLogiX's drug development pipeline, targeting multiple myeloma - the sec...
2021-09-09 05:00
2824
Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Androgenetic Alopecia Was Met
SUZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced the primary endpoint of phase II clinical trial of pyrilutamide ("KX-8...
2021-09-08 22:13
4977
Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
-- First participants enrolled in Phase 1 clinical trial of combination NanoFlu™/NVX–CoV2373 vaccine with Matrix-M™ adjuvant -- Phase 1/2 study will evaluate immunogenicity and safety GAITHERSBURG, Md., Sept. 8, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated...
2021-09-08 20:30
6697
Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets
SHANGHAI, Sept. 8, 2021 /PRNewswire/ -- Huadong Medicine (SZ.000963) and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that the companies have entered into a co-development partnership to accelerate the discovery of brea...
2021-09-08 20:08
4977
The Valens Company Achieves Access to GMP Manufacturing in Australia & Expands International Footprint to Asia-Pacific through Exclusive Partnership with Epsilon Healthcare
Partnership will bring first GMP manufactured products to be sold through Valens in bothAustralia and New Zealand Access to Epsilon's GMP facility in Australia to provide Valens with future access to global markets includingLatin America, Europe, UK and Asia-Pacific KELOWNA, BC, Sept. 8, 2021 ...
2021-09-08 19:00
4338
HICOOL 2021 Global Entrepreneur Summit
BEIJING, Sept. 8, 2021 /PRNewswire/ -- HICOOL 2021 Global Entrepreneur Summit, a global event for entrepreneurs, will be held inBeijing on September 10-11, 2021, at the Beijing International Exhibition Center (New Venue) in Shunyi, Beijing, with the theme "Connect Startups Worldwide, Innovate Bei...
2021-09-08 16:30
2442
Yiling Pharmaceutical's Yishen Yangxin Anshen Tablets Granted Drug Certificate
SHIJIAZHUANG, China, Sept. 8, 2021 /PRNewswire/ -- Yiling Pharmaceutical recently announced that its newly-developed drug Yishen Yangxin Anshen Tablet had been granted official drug certificate byChina's National Medical Products Administration (NMPA). With the functions of reinforcing kidney, n...
2021-09-08 12:28
3373
Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors
NORTH BRUNSWICK, New Jersey and HANGZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the Phase Ia clinical trial in the U.S. to evaluate the triple ...
2021-09-08 11:04
3159
Bactiguard appoints new CEO
The Board of Bactiguard Holding AB (publ) has today appointed Anders Göransson as the new CEO. Anders has extensive experience from consulting within McKinsey and has held several senior positions in Amgen, most recently as Head of Innovation Europe. Anders will start his employment in Bactiguard...
2021-09-08 09:51
3129
NCCN Shares Latest Expert Recommendations for Prostate Cancer in Spanish and Portuguese
PLYMOUTH MEETING, Pa., Sept. 8, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit alliance of leading cancer centers in the United States—announces recently-updated versions of evidence- and expert consensus-based guidelines for treating prostate cancer,translate...
2021-09-08 09:37
2265
Gannex Announces Positive Topline Results from the U.S. Phase I Trial of Drug-Drug Interactions in Healthy Subjects and Pharmacokinetics in Patients with NAFLD for Its THRβ Agonist ASC41
SHANGHAI, Sept. 8, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces positive topline results from the U.S. Phase I trial of drug-drug interactions in healthy subjects and pharmacokinetics (PK) in patients with non-alcoholic fatty liver dise...
2021-09-08 08:30
4482
Innovent Announces First Patient with Type 2 Diabetes Dosed in a Phase 2 Clinical Trial of IBI362 (a GLP-1R and Glucagon Receptor Dual Agonist) in China
SAN FRANCISCO and SUZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2021-09-08 08:00
8381
Stem Cells for Everyone: I Peace expands its clinical-grade iPSC banking service leveraging mass manufacturing capability
PALO ALTO, Calif., Sept. 7, 2021 /PRNewswire/ -- I Peace, Inc. (CEO: Koji Tanabe , https://ipeace.com/), aPalo Alto-based biotech startup focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) expands its personalized iPSC banking service. I Peace launched its clinica...
2021-09-08 02:00
2023
First-of-its-Kind, Global Data Repository for Interstitial Lung Diseases Launches Through Academic and Industry Collaborative
HOLLAND, Mich., Sept. 7, 2021 /PRNewswire/ -- The Open Source Imaging Consortium (OSIC) today announced the launch of its global, data-rich repository of anonymized HRCT scans and clinical information regarding interstitial lung diseases (ILDs). This first-of-its-kind database is the world's lar...
2021-09-07 23:00
4027
Further Study in humans shows that the DTH response, the basis for CoviDTH, is highly durable and persists for at least one year after COVID-19 exposure or vaccine administration
VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Sept. 7, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that the Scientific Advisor for its CoviDTH program,Yvelise Barrios, MD, PhD, and Clinical Immuno...
2021-09-07 20:00
7148
Medwish.com Launches Global Free Shipping Plan to Deliver Medical Equipment to Hospitals
SHANGHAI, Sept. 7, 2021 /PRNewswire/ -- Medwish.com, the online B2B medical equipment marketplace, today announced it will offer free shipping on more than 10,000 medical products in its full 14 sub-categories covering hospital beds, patient monitors, compressor nebulizers, oxygen concentrators, ...
2021-09-07 19:26
3324
Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients
DURHAM, N.C. and BEIJING, Sept. 7, 2021 /PRNewswire/ -- Brii Biosciences
2021-09-07 19:04
5927
RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
- COVID-19 and long COVID patients are at increased risk of developing kidney damage - Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model - Renal fibrosis is a progressive process which occurs in patients with chronic kidney disease (CKD) and can ultimately lead to ...
2021-09-07 19:00
3644
Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation
HONG KONG, Sept. 7, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end artificial intelligence (AI) -driven drug discovery company, specialized in target discovery, small molecule chemistry, and clinical development, announced a collaboration with theUniversity of Cambridge. The agreement out...
2021-09-07 18:15
3638
Week's Top Stories
Most Reposted
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 309 media titles]
2026-07-30 10:45
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
[Picked up by 295 media titles]
2026-08-04 07:00
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 294 media titles]
2026-07-30 15:00Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
[Picked up by 291 media titles]
2026-08-04 14:30
Most Read
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
2026-07-30 10:45
18866
